A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Genentech

Status and phase

Completed

Phase 1

Conditions

Metastatic Colorectal Cancer

Treatments

Drug: bevacizumab

Drug: PRO95780

Drug: FOLFOX

Study type

Interventional

Funder types

Industry

Identifiers

NCT00851136

APM4566g

Details and patient eligibility

About

This will be a multicenter, open-label study enrolling a total of up to 23 patients.

Enrollment

9 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically confirmed CRC with evidence of locally advanced recurrent or metastatic disease and measurable tumor lesions
Life expectancy > 3 months
For patients of reproductive potential (males and females), use of reliable means for contraception throughout the trial and for 6 months following their final exposure to study treatment
Willingness and capability to be accessible for study follow-up

Exclusion criteria

Prior 5-FU, capecitabine, and/or oxaliplatin treatment with the exception of: prior oxaliplatin treatment≤ 6 weeks in the advanced or metastatic setting; prior treatment with 5-FU, capecitabine, and/or oxaliplatin in the adjuvant setting if relapse occurred > 6 months from concluding adjuvant therapy
Peripheral neuropathy Grade ≥ 2
Prior radiotherapy to a measurable metastatic lesion(s) to be used for response assessment, unless the lesion has progressed subsequent to the radiotherapy
Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1, or radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to Cycle 1, Day 1
Chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to Cycle 1, Day 1
Evidence of clinically detectable ascites
Other invasive malignancies within 5 years prior to Cycle 1, Day 1
History or evidence upon physical examination of active central nervous system (CNS) disease
Current or recent participation in another experimental drug study
Clinically significant cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia within 1 year prior to Cycle 1, Day 1, or Grade II or greater peripheral vascular disease
Active infection requiring parenteral antibiotics
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Cycle 1, Day 1, fine needle aspirations within 7 days prior to Cycle 1, Day 1, or anticipation of need for major surgical procedure during the course of the study
Known or suspected to be positive for the human immunodeficiency virus (HIV)
Known to be positive for hepatitis C or hepatitis B surface antigen
Inadequately controlled hypertension
Prior history of hypertensive crisis or hypertensive encephalopathy
History of arterial thromboembolic event 6 months prior to Cycle 1, Day 1
History of abdominal fistula or gastrointestinal perforation within 6 months prior to Cycle 1, Day 1
Bleeding diathesis or coagulopathy
Pregnancy (positive pregnancy test) or breast feeding
Serious, non-healing wound, ulcer, or bone fracture